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ABSTRACT
Colorectal cancer remains the third most common malignancy and the fourth most
common cause of cancer mortality worldwide. Dysregulated miRNA levels are
associated with several types of malignancies and may serve as important biomarkers
and/or therapeutic targets in colorectal cancer. We examined the role of miRNA-155 on
tumorigenesis and associated symptoms using a well-characterized mouse model of
colorectal cancer. C57BL/6 wild-type mice and miRNA-155-/- mice (n=7-13 group) were
given a single injection of AOM (10mg/Kg) followed by 3 cycles of DSS (2% in the
water for 1 week followed by 2 weeks of plain water). A C57BL/6 wild-type group that
did not receive AOM/DSS treatment was also included as a comparison (n=5). Mice
were monitored twice weekly for body weight changes and symptom severity. Prior to
sacrifice, body composition measurements were taken. At sacrifice, colon tissue, spleen,
and adipose tissue were harvested. miRNA-155-/- mice had significantly fewer tumors
than wild-type mice. In addition, miRNA-155-/- mice exhibited a lower symptom
severity score and a greater body weight gain than wild-type mice over the course of the
experiment. In general, wild-type mice had a reduction in fat mass and percent body fat
as well as fat pad weights compared to the disease-free controls but miRNA-155
completely offset this effect. If these findings can be clinically translated, miRNA-155
may lead to an effective clinical biomarker and/or therapeutic target in colorectal cancer.
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CHAPTER 1
INTRODUCTION
Colorectal cancer remains a significant global health concern; despite advances in
screening, surgery and treatment and recent reductions in mortality, it remains the third
most common malignancy and the fourth most common cause of cancer mortality
worldwide 6, 7, 14, 18. In the US alone in 2013, it is estimated that over 142,000 new cases
of colorectal cancer will be diagnosed and that there will be over 50,000 deaths from the
disease. These statistics can be attributed largely to the lack of uptake of effective
screening modalities (especially colonoscopy) that are available for prevention, detection,
and diagnosis,23, 24 and the fact that colorectal cancer symptoms are rare in the early
stages so non-screening-detected cancers tend to present in late stage when treatments are
ineffective13. Identifying new targets that may play a role in the development and
progression of colorectal cancer is of significant public health concern, not only from a
treatment point of view but also for the development of potential biomarkers that can be
used for assessment and diagnosis of the disease 15.
Mammalian miRNAs are noncoding RNA oligonucleotides that have emerged as
potent regulators of gene expression 20. Consequently, dysregulated miRNA levels are
associated with several types of malignancies 3, 15, 21. For example, in a recent report
miRNA-155 was significantly higher in breast cancer tissue than in corresponding nontumor tissue and high miRNA-155 expression was correlated with higher tumor grade,
advanced tumor stage and lymph node metastasis 4. And further, the disease-free and
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overall survival rates of the high miRNA-155 group were significantly lower than those
of the low microRNA-155 group 4. Another study reported that expression of miRNA155 promoted the proliferation of breast cancer cells in vitro as well as the development
of tumors in nude mice 8. While there is accumulating evidence to suggest a role for
miRNA-155 in the development of breast cancer, there are relatively fewer studies that
report a link between miRNA-155 and colorectal cancer. A recent report, however, does
indicate that miRNA-155 is increased in human colorectal cancer samples indicating that
it may be involved in the progression and development of colorectal cancer 22 but to date
there have been no studies done in animals to implicate a causal relationship.
The purpose of this study was to examine the role of miRNA-155 on the
development of colorectal cancer. For this, we used a well-established mouse model of
colorectal cancer, the azoxymethane (AOM) + dextran sodium sulfate (DSS) chemicallyinduced model 12, 16, 17. This model recapitulates the phases of initiation and progression
of the tumor that occurs in humans 12, 16, 17 . A miRNA-155 knockout mouse was used to
examine the role of miRNA-155 on colorectal cancer. We hypothesized that lack of
miRNA-155 would lead to a decrease in sickness symptoms along with a reduction in
tumorigenesis. In this report, we demonstrate that miRNA-155 plays a necessary role in
the development of colorectal cancer given our findings of a reduction in tumor number
in miRNA-155 knockout mice. This miRNA may serve as an important biomarker
and/or therapeutic target in colorectal cancer.

2

CHAPTER 2
MATERIALS AND METHODS
Animals. C57BL/6 wild-type mice and miRNA-155-/- mice on a C57BL/6
background were bred in the University of South Carolina’s Center for Colon Cancer
Research (CCCR) Mouse Core Facility. miRNA-155-/- offspring were genotyped as null
homozygotes by RT-PCR for the miRNA-155 gene by taking tail snips at weaning. The
primer sequences for miRNA-155 were as follows: miRNA-155-/- 5'-GTG CTG CAA
ACC AGG AAG G-3', miRNA-155+/- 5'- CTG GTT GAA TCA TTG AAG ATG G-3',
and wild-type 5'- CGG CAA ACG ACT GTC CTG GCC G-3'. Mice were maintained on
a 12:12h light-dark cycle in a low-stress environment (22oC, 50% humidity and low
noise) and provided food (AIN-76A) and water ad libitum. All animal experimentation
was approved by the University of South Carolina's Institutional Animal Care and Use
Committee.
AOM/DSS protocol. An azoxymethane (AOM) + dextran sodium sulfate (DSS)
chemically induced model of colorectal cancer was used 12, 16, 17. C57BL/6 wild-type
mice and miRNA-155-/- mice (n=7-13 group) began their AOM/DSS treatment at 10
weeks of age. Briefly, mice were given a single injection of AOM (10mg/Kg) followed
by 3 cycles of DSS (2% in the water for 1 week followed by 2 weeks of plain water) as
previously described 12, 16, 17. A C57BL/6 wild-type group that did not receive AOM/DSS
treatment was also included as a comparison (n=5).
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Body Weight and Food & Fluid Intake. Mice were weighed twice a week
throughout the 10 week colorectal cancer protocol. Food and fluid intake were monitored
once a week.
Body Composition. Body composition was assessed at twenty weeks (following
the 10 week colorectal cancer protocol and prior to sacrifice). For this procedure, mice
were placed under brief anesthesia (isoflurane inhalation) and were assessed for lean
mass, fat mass, and body fat percentage via dual-energy x-ray absorptiometry (DEXA)
(Lunar PIXImus, Madison, WI) 5.
Symptom Scoring. Symptoms were scored twice weekly throughout the 10 week
protocol using a standard scoring system that has previously been used in this model.
Briefly, scores were based on diarrhea, blood in stools and weight loss (see Table 1).
Diarrhea symptoms were evaluated based on visualization of the fecal matter. Blood in
the stools was determined using a Hemoccult Fecal occult blood test. In addition, weight
loss was based on the percent change in weight compared to baseline levels. Mice were
given scores of 0, 2 or 4 depending on the severity of the symptoms.
Tissue Collection. At 20 weeks of age, mice were sacrificed for tissue collection.
Epididymal, mesentery, and retroperitoneal fat pads as well as the spleen were removed,
weighed, and immediately snap-frozen in liquid nitrogen and stored at -80°C or fixed in
10% formalin. The large intestine was removed from the distal end of the cecum to the
anus and mesentery tissue was removed with tweezers. It was flushed with PBS, opened
longitudinally, and flattened with a cotton swab. All large intestines were fixed in 10%
buffered formalin (Fisher Scientific, Pittsburg, PA) for 24 h.
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Tumor Characteristics. Formalin-fixed large intestines were rinsed in deionized
water, briefly stained in 0.1% methylene blue, and counted by the same investigator who
was blinded to the treatments. Tumors were counted under a dissecting microscope, using
tweezers to pick through the intestinal villi and identify tumors. Tumors were categorized
by size (>2 mm, 1–2 mm, and <1 mm). Colon lengths were measured as an indicator of
inflammation; a shorter colon length is indicative of greater inflammation. Similarly,
colon weight was determined as an increase in colon weight has been associated with
elevated inflammation.
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CHAPTER 3
RESULTS
Body Weight. Body weight was monitored twice weekly throughout the 10 week
AOM/DSS protocol. Body weight over time is expressed as a percent of baseline (i.e.
normalized to measured body weight prior to the initiation of the AOM/DSS protocol)
(Figure 1A). In general, the disease-free control group gained weight at a greater rate
than both of the AOM/DSS groups; this was significant at most of the time-points
measured. When comparing between the AOM/DSS groups, the miRNA-155-/- mice
had a greater body weight gain than the wild-type mice at 15.5, 18.5, 19.0 and 19.5 weeks
(P<0.05). We also measured body weight at sacrifice (Figure 2A). As expected, the
wild-type AOM/DSS mice had a decrease in body weight compared to the disease-free
control wild-type mice (25.47 g versus 31.30 g) (P<0.05) and miRNA-155-/- offset this
effect; the miRNA-155-/- mice were very similar in weight at end point to the diseasefree wild-type control mice (Figure 2A).
Symptom Severity. Symptoms, including diarrhea, blood in stools and weight
loss, were scored twice weekly throughout the 10 week AOM/DSS protocol. In general,
miRNA-155-/- mice exhibited a lower symptom severity score than wild-type mice over
the course of the experiment (Figure 1B); this reached statistical significance at 12.5,
14.5, 15, 15.5, 18, 18.5, 19.5 and 20 weeks of age (P<0.05).
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Spleen Weight. Spleens were harvested and weighed at sacrifice. Spleen weight,
expressed as a percentage of body weight was increased in the wild-type AOM/DSS mice
compared to disease-free control mice and this effect was offset in the miRNA-155-/AOM/DSS mice (Figure 2B). However, these effects did not reach statistical
significance.
Body Composition. Prior to sacrifice at 20 weeks of age, mice underwent a
DEXA scan to determine body composition (body fat percentage, fat mass and lean mass)
(Figure 3). This was performed as cachexia has been associated with severity of disease
in colorectal cancer. As expected, the wild-type AOM/DSS mice had a decrease in fat
mass compared to the disease-free control mice (4.03 ± 0.3 gm vs. 7.16 ± 0.9 gm)
(P<0.05) and miRNA-155-/- offset this effect; the miRNA-155-/- mice had a very similar
fat mass (6.48 gm) to the disease-free control mice (Figure 3A). Similar effects were
observed for body fat percentage. The wild-type AOM/DSS mice had a decrease in body
fat percentage compared to the disease free controls (17.45 ± 0.8% vs. 24.98 ± 2.3%)
(P<0.05) and this effect was negated in the miRNA-155-/- mice (22.81 ± 1.9%) (Figure
3B). There were no significant group differences detected for lean mass at any of the
time points (Figure 3C).
Visceral Fat Weights. At sacrifice, epididymal, mesenteric, and retroperitoneal
fat pads were collected and weighed. This was done to monitor the degree of fat loss,
which has been associated with poor outcome in colorectal cancer. As expected,
epididymal fat mass was decreased in the wild-type AOM/DSS mice compared to the
disease-free control group (P<0.05) and this effect was offset in the miRNA-155-/- mice
(Figure 4A). In fact, there was no difference between the disease-free control mice and
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the miRNA-155-/- mice that underwent the AOM/DSS protocol. Similar effects were
found for mesenteric (Figure 4B) and kidney fat (Figure 4C); in both cases, the fat mass
was reduced in wild-type AOM/DSS mice versus the disease free control mice (P<0.05)
and deficiency of miRNA-155 completely offset this effect.
Tumor Characteristics. At 20 weeks of age, mice were sacrificed and the large
intestine (colon) was harvested and tumors were counted on formalin-fixed, methylene
blue-stained sections. miRNA-155-/- mice had significantly fewer tumors than wild-type
mice (0.17 versus 2.14) (P<0.05) (Figure 5A). Tumors were also stratified according to
size (Figure 5B); we classified tumors as being large (> 2mm in diameter), medium (<2 >
1 mm in diameter) or small (< 1 mm in diameter). A significant percentage of the tumors
found in the wild-type AOM/DSS mice were considered to be large and the only tumors
present in the miRNA-155-/- mice were medium size (Figure 5B). After the tumors were
counted, the colons were then weighed and measured according to length and width
(mm). The colon weight (g) was measured as an indication of the amount of
inflammation present. The wild-type AOM/DSS mice had a significantly (P<0.05)
heavier colon weight than the disease-free control mice (Figure 5C) but there was no
effect of genotype; there was no difference between the wild-type AOM/DSS mice and
the miRNA-155-/- AOM/DSS mice. Then a colon length: width ratio was calculated as it
has been documented that the colon length decreases with inflammation. Both of the
AOM/DSS groups showed an increase in colon length: width ratio compared to the
disease free controls (Figure 5D).
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CHAPTER 4
DISCUSSION
Dysregulated miRNA levels are associated with several types of malignancies
including colorectal cancer 3, 21. Several recent reports have indicated that miRNA-155
is correlated with higher tumor grade, advanced tumor state and lymph node metastasis in
breast cancer. Although there is accumulating evidence to suggest a role for miRNA-155
in the development of breast cancer, there are relatively fewer studies that report a link
between miRNA-155 and colorectal cancer. Therefore, we examined the role of miRNA155 on body weight, body composition, symptom severity and tumorigenesis using a well
characterized chemically-induced mouse model of colorectal cancer 12, 16, 17. Our data
indicates that miRNA-155 plays a significant role in tumorigenesis as well as the
symptoms associated with colorectal cancer; mice deficient for miRNA-155 had a
significant reduction in the number of tumors in the colon and this was associated with
decreased sickness symptoms and prevention of loss of body weight and fat mass that can
accompany the disease.
Knockout mice provide a tool to examine the effects of various genes on
tumorigenesis. We used miRNA-155 knockout mice to examine the role of this miRNA
on colorectal cancer using a well-characterized chemically-induced mouse model (i.e. the
AOM/DSS model) 12, 16, 17. The miRNA-155-/- mouse is available in a C57BL/6
background, a strain that shows high incidence and multiplicity of colonic
adenocarcinoma following AOM/DSS administration. The AOM/DSS model is a two-
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stage mouse colorectal carcinogenesis model initiated with AOM and promoted by DSS
that was developed to obtain a better understanding of the pathogenesis of inflammatory
bowel-related colorectal cancer. In this model, mice initiated with a low dose of a
colonic carcinogen, AOM (10 mg/kg body wt), develop tumors after a relatively shortterm DSS exposure. The subsequent dysplasia and neoplasms show positive staining for
β-catenin, COX - 2 and inducible nitric oxide synthase. Our data indicates that mice
deficient for miRNA-155 have fewer overall tumors than wild-type mice. In fact, they
were approximately 90% lower than those of wild-type mice. When tumors were
stratified according to size, miRNA-155-/- mice had significantly lower numbers of
smaller tumors as well as larger tumors and although medium tumor number was also
lower in miRNA-155-/- mice, this did not reach statistical significance. While we did
observe an increase in colon weight and an increase in the colon length: width ratio in the
AOM/DSS treated mice compared to the disease free control mice, we did not see an
effect of genotype within the AOM/DSS groups. This was surprising given that an
increase in these outcomes is indicative of inflammation and has been associated with
increased tumor number. This may be explained by the overall low incidence of tumors
in these mice; perhaps a greater number of tumors are needed to clearly observe
differences in inflammatory outcomes between these groups. Even so, to our knowledge
this is the first report of a benefit of miRNA-155 deficiency in a controlled experimental
mouse model of colorectal cancer.
We also examined symptom severity during the course of the AOM/DSS
protocol. Symptoms were recorded twice weekly and included scoring for diarrhea,
blood in stools and weight loss. The presence of these symptoms is not unusual in
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patients with colorectal cancer. In fact, diarrhea, blood in stools and weight loss are a
direct result from colorectal cancer. The existence of tumors as well as the reduction of
villi in the colon results in a reduced ability to absorb nutrients during digestion, which
can lead to diarrhea and weight loss. Also large tumors can cause bleeding during
digestion; when the fecal matter is passing through the colon it can catch on the larger
tumors causing the presence of blood in the stool especially if there is an absence of villi
in the colon. Greater symptom scores indicate increased severity of the cancer. In the
wild-type mice, the severity of these symptoms was by far greater than that of the
miRNA-155-/- mice following the AOM/DSS protocol. These results imply that
miRNA-155 may serve as an important therapeutic target in colorectal cancer; blocking
miRNA-155 may reduce the severity of symptoms in colorectal cancer patients.
Body composition was also examined as weight loss, including fat loss, has been
associated with colorectal cancer. Cancer cachexia is a wasting disorder in which
patients have a significantly decreased appetite without actively trying to lose weight 1, 2,
10

. In fact, patients with cancer cachexia lose a significant amount of weight quickly even

when an increased caloric intake is administered. One of the determining factors of
cachexia is the loss of lean fat mass while consuming a high calorie diet. Although in the
current experiment we did not observe a significant decrease in lean mass in the wildtype AOM/DSS mice compared to the disease-free control group there was a trend
towards a decrease. Whereas the miRNA-155-/- had a very similar lean mass to the
disease-free control mice. There was however, a significant decrease in fat mass as well
as body fat percentage observed in the wild-type mice that were not seen in the miRNA155-/- mice. In addition, epididymal, mesenteric and kidney fat weight were all reduced
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at sacrifice in the wild-type group and miRNA-155-/- offset this effect. In general, the
miRNA-155 knockout mice had a more similar body composition to the disease-free
control group than the wild-type group of mice. This suggests that targeting miRNA-155
in colorectal cancer patients could possibly reduce the occurrence of cancer cachexia
allowing patients a greater chance of maintaining a stable body composition.
While we did not explore specific mechanisms of action that may be contributing
to benefits of miRNA-155 deficiency in this model there are several possible
explanations. Firstly, miRNA-155 may be promoting angiogenesis 9. For example, it
has been reported that miRNA-155 can downregulate von Hippel-Lindau (VHL) tumor
suppressor in breast cancer 9. VHL acts through stimulating hypoxia-inducible factor
(HIFα) family proteins to inhibit the stimulation of vascular endothelial growth factor
(VEGF), an important promoter of angiogenesis 9. Secondly, it has been shown to downregulate the tumor suppressor CDC73 in various cancer models 11. For instance,
expression of miRNA-155 in a squamous cell carcinoma cell line dramatically reduced
CDC73 levels, enhanced cell viability, and decreased apoptosis. Conversely, the delivery
of a miRNA-155 antagonist (antagomir-155) to cells overexpressing miRNA-155
resulted in increased CDC73 levels, decreased cell viability, increased apoptosis, and
marked regression of xenografts in nude mice 11. Thirdly, miRNA-155 has been reported
to be a positive regulator of inflammatory processes 8, 19. One study reported that both
miRNA-155 overexpression and an inflammatory environment increased the frequency
of mutations and down-regulated a kinase that blocks cell-cycle progression indicating
that miRNA-155 may be a key player in the treatment of inflammation-related cancers 19.
Similarly, a recent study reported that miRNA-155 expression is inversely correlated with
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expression of suppressor of cytokine signaling (SOCS1), a negative regulator of
inflammation, in breast cancer cell lines as well as in a subset of primary breast tumors 8.
While our data shows promising effects for a benefit of miRNA-155 deficiency
on colorectal cancer and associated symptoms there are several limitations of this study.
Firstly, we did not investigate potential targets of miRNA-155 or mechanisms of action
of miRNA-155 in this model; this study was limited to examination of tumor number and
symptom severity. Secondly, the mice developed relatively few tumors, which may have
precluded observation of the true effects of miRNA-155 deficiency. Therefore this study
should be repeated with higher doses of AOM and/or DSS to enhance tumorigenesis.
Further, pathways and mechanisms whereby miRNA-155 may have mediated its effects
on colorectal cancer should be explored. Lastly, anytime a global knockout mouse model
is used there is always some speculation as to the clinical translation; having absolutely
no presence of miRNA-155 may not fully show what the effects of possible therapeutics
would provide in a human.
In summary, our data indicates that miRNA-155 plays a significant role in
tumorigenesis as well as the symptoms associated with colorectal cancer; mice deficient
for miRNA-155 had a significant reduction in the number of tumors in the colon and this
was associated with decreased sickness symptoms and prevention of loss of body weight
and fat mass that accompany the disease. Future research should be performed to
confirm these findings along with the examination of the mechanisms of action of
miRNA-155. If these findings can be clinically translated miRNA-155 may lead to an
effective clinical biomarker and/or therapeutic target in colorectal cancer.
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TABLE 1. SYMPTOM SCORING
Symptom Scoring
Diarrhea

0
Well-formed pellet

Blood in stools
Weight Loss

No blood
0-5% weight loss

2
Pasty and semiformed stools that
do not adhere to the
anus
Positive hemoccult
11-15% weight loss

14

4
Liquid stools that
adhere anus

Gross bleeding
>20% weight loss
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